There are many ways by which the body responds to abnormal cells or foreign invaders. One mechanism involves the T-cells of the immune system, which have proteins on their surface called “checkpoint proteins.” These checkpoint proteins bind to proteins on the surface of other cells, and this can result in either stimulation or suppression of T-cell activity. Stimulation of the T-cells leads to the destruction of abnormal or invading cells, while suppression is a built-in mechanism to prevent the immune system from attacking the body’s own normal cells.
Tumor cells, however, can sometimes display surface proteins which outwit the immune system by binding to T-cells and suppressing their activity; this allows the tumor cells to grow and spread. In recent years, “immune checkpoint inhibitor” antibodies (ICIs) have been developed which will block tumor cell binding to the T-cells. In effect, this re-activates the T-cell’s immune response to destroy tumor cells. In the United States, ICIs have been used successfully to treat cancers in the kidney, bladder, liver and head or neck areas (Han, 2022).
The major factors attributing to the growth of the immunotherapy drugs market are the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars, rising prevalence of chronic diseases and lifestyle disorders, and rising demand for monoclonal antibodies. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, need critical care during hospitalization. For instance, according to the GLOBOCAN 2020 data, globally, in 2020, the total number of new cancer cases was found to be 9,227,484, indicating that it had risen to 19.3 million cases and 10 million cancer deaths in 2020. Lung cancer and prostate cancer are the most common among men, accounting for nearly one-third of all male cancers.
The current trends of nanotechnology in immunotherapy will boost market growth. The nanoparticles, which have dimensions of less than 100 nanometers, have been engineered to treat cancer. The benefits provided are active or passive attack of drugs, high solubility bioavailability, and multifunctionality.
North America is expected to have a significant market share throughout the forecast period. This is due to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region (IMMUNOTHERAPY DRUGS MARKET – GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 – 2027), 2022).
Overall, the rising R&D activities in developing novel immunotherapies for various chronic diseases are anticipated to drive the global immunotherapy drugs market’s growth.
Regarding technology, nonviral gene delivery and nucleic acid delivery offer significant advantages in terms of safety, particularly from immunogenicity and carcinogenicity. The plurality of gene delivery systems is broadly benchmarked in terms of transfection efficiency, precision in cancer immunotherapy, and capability to pass the membrane barrier. As for remarkable innovation in biotech platforms, the research highlights gene addition as a novel approach that uses a delivery system to insert new genes directly into cells. The addition of a functional gene can take place either outside (ex vivo) or inside (in vivo) the body and can be used in cancer immunotherapy through CAR T-cell technology.
A remarkable number of companies succeeded in the targeted immunotherapy space. A competitive analysis of the top three innovators, based on their IP activity and patent innovation focus, is included. Funding and investment, including leading deals and investors focused on the technologies empowering targeted immunotherapies, are also covered (Wood, 2022).
Han, S. (2022, August 1st). Destroying tumor cells: Targeted immunotherapy using injectable materials. EurekAlert! Retrieved August 5th from https://www.eurekalert.org/news-releases/960547
IMMUNOTHERAPY DRUGS MARKET – GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 – 2027). (2022, 2021). MorderIntelligence. Retrieved August 4th from https://mordorintelligence.com/industry-reports/immunotherapy-drugs-market#:~:text=The%20major%20factors%20attributing%20to%20the%20growth%20of,lifestyle%20disorders%2C%20and%20rising%20demand%20for%20monoclonal%20antibodies.
Wood, L. (2022, January 17th 2022). Targeted Immunotherapy in Oncology Market Research Report 2021: Development of New Targeted Immunotherapies, Particularly Those that Deliver Therapeutic DNA and Proteins – ResearchAndMarkets.com. Retrieved August 4th from https://finance.yahoo.com/news/targeted-immunotherapy-oncology-market-research-150600103.html